Biocatalytic Asymmetric Synthesis of Chiral Amines from Ketones Applied to Sitagliptin Manufacture

Biocatalytic Boost Enzymes tend to direct reactions toward specific products much more selectively than synthetic catalysts. Unfortunately, this selectivity has evolved for cellular purposes and may not promote the sorts of reactions chemists are seeking to enhance (see the Perspective by Lutz). Siegel et al. (p. 309) now describe the design of enzymes that catalyze the bimolecular Diels-Alder reaction, a carbon-carbon bond formation reaction that is central to organic synthesis but unknown in natural metabolism. The enzymes display high stereoselectivity and substrate specificity, and an x-ray structure of the most active enzyme confirms that the structure matches the design. Savile et al. (p. 305, published online 17 June) applied a directed evolution approach to modify an existing transaminase enzyme so that it recognized a complex ketone in place of its smaller native substrate, and could tolerate the high temperature and organic cosolvent necessary to dissolve this ketone. This biocatalytic reaction improved the production efficiency of a drug that treats diabetes. An engineered enzyme offers substantial efficiency advantages in the production-scale synthesis of a drug. Pharmaceutical synthesis can benefit greatly from the selectivity gains associated with enzymatic catalysis. Here, we report an efficient biocatalytic process to replace a recently implemented rhodium-catalyzed asymmetric enamine hydrogenation for the large-scale manufacture of the antidiabetic compound sitagliptin. Starting from an enzyme that had the catalytic machinery to perform the desired chemistry but lacked any activity toward the prositagliptin ketone, we applied a substrate walking, modeling, and mutation approach to create a transaminase with marginal activity for the synthesis of the chiral amine; this variant was then further engineered via directed evolution for practical application in a manufacturing setting. The resultant biocatalysts showed broad applicability toward the synthesis of chiral amines that previously were accessible only via resolution. This work underscores the maturation of biocatalysis to enable efficient, economical, and environmentally benign processes for the manufacture of pharmaceuticals.

[1]  Y. Ikenaka,et al.  Microbial synthesis of chiral amines by (R)-specific transamination with Arthrobacter sp. KNK168 , 2005, Applied Microbiology and Biotechnology.

[2]  Feng Xu,et al.  Highly efficient asymmetric synthesis of sitagliptin. , 2009, Journal of the American Chemical Society.

[3]  Paul H. Moran,et al.  Industrial-scale synthesis and applications of asymmetric hydrogenation catalysts. , 2007, Accounts of chemical research.

[4]  John D. Hayler,et al.  Key green chemistry research areas—a perspective from pharmaceutical manufacturers , 2007 .

[5]  W. Stemmer,et al.  Directed evolution of a fucosidase from a galactosidase by DNA shuffling and screening. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Manfred K. Warmuth,et al.  Engineering proteinase K using machine learning and synthetic genes , 2007, BMC biotechnology.

[7]  J. Rozzell,et al.  Biocatalytic production of amino acids and derivatives , 1992 .

[8]  W. Kroutil,et al.  Deracemisation of α‐Chiral Primary Amines by a One‐Pot, Two‐Step Cascade Reaction Catalysed by ω‐Transaminases , 2009 .

[9]  Jeffrey C. Moore,et al.  Rapid screening and scale-up of transaminase catalysed reactions. , 2009, Organic & biomolecular chemistry.

[10]  Wolfgang Kroutil,et al.  Asymmetric Synthesis of Optically Pure Pharmacologically Relevant Amines Employing ω‐Transaminases , 2008 .

[11]  E. Round,et al.  Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis , 2008, BMC endocrine disorders.

[12]  V. Eijsink,et al.  Rational engineering of enzyme stability. , 2004, Journal of biotechnology.

[13]  J. Shin,et al.  Exploring the active site of amine:pyruvate aminotransferase on the basis of the substrate structure-reactivity relationship: how the enzyme controls substrate specificity and stereoselectivity. , 2002, The Journal of organic chemistry.

[14]  John C Whitman,et al.  Improving catalytic function by ProSAR-driven enzyme evolution , 2007, Nature Biotechnology.

[15]  Paul N Devine,et al.  Advances in the enzymatic reduction of ketones. , 2007, Accounts of chemical research.

[16]  G. Guebitz,et al.  Formal asymmetric biocatalytic reductive amination. , 2008, Angewandte Chemie.

[17]  Jack Liang,et al.  Practical chiral alcohol manufacture using ketoreductases. , 2010, Current opinion in chemical biology.

[18]  R. Rosenfeld.  Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[19]  Juhan Kim,et al.  Redesigning the substrate specificity of ω‐aminotransferase for the kinetic resolution of aliphatic chiral amines , 2008, Biotechnology and bioengineering.

[20]  Zhilei Chen,et al.  Rapid creation of a novel protein function by in vitro coevolution. , 2005, Journal of molecular biology.

[21]  R. Bergenstal,et al.  Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. , 2009, European journal of internal medicine.

[22]  Oliver May,et al.  Biocatalytic reductions: from lab curiosity to "first choice". , 2007, Accounts of chemical research.

[23]  Karen Robins,et al.  Efficient Asymmetric Synthesis of Chiral Amines by Combining Transaminase and Pyruvate Decarboxylase , 2008, Chembiochem : a European journal of chemical biology.

[24]  Ian W Davies,et al.  Looking Forward in Pharmaceutical Process Chemistry , 2009, Science.

[25]  Claes Gustafsson,et al.  Semi-synthetic DNA shuffling of aveC leads to improved industrial scale production of doramectin by Streptomyces avermitilis. , 2005, Metabolic engineering.